drugset / Trial / NCT06659562
Clinical Study of HER-096 in Healthy Volunteer Subjects and Patients With Parkinson's Disease
Phase 1
Completed
32 enrolled
Herantis Pharma Plc.
BC Platforms · collabClinical Research Services Turku - CRST Oy · collabOy Medfiles Ltd · collab
RandomizedSequentialQuadruple-blindTreatment
Summary
In this clinical study, the safety and tolerability of HER-096 and the way the body interacts with the drug (pharmacokinetics) will be investigated. The clinical study consists of two parts. In Part 1, the drug HER-096 is given as a single dose to healthy volunteer subjects. In Part 2, HER-096 or placebo (physiological saline) is given as multiple doses during a 4-week period to patients with Parkinson´s disease. The doses are given as injections under the skin (subcutaneous injection).
Timeline
- Start
- 2024-09-23
- Primary completion
- 2025-08-14
- Completion
- 2025-08-20
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Comparator | HER-096 | Unknown | — | Subcutaneous |